<DOC>
	<DOCNO>NCT02533674</DOCNO>
	<brief_summary>Prospective , open-label , dose-ranging , uncontrolled phase I study escalate dos PM060184 combination gemcitabine select patient advance solid tumor . The study objective : To determine MTD RD PM060184 combination gemcitabine select patient advance solid tumor . To characterize safety profile feasibility combination study population . To characterize pharmacokinetics combination detect major drug-drug PK interaction . To obtain preliminary information clinical antitumor activity combination .</brief_summary>
	<brief_title>Multicenter , Open-label , Clinical Pharmacokinetic Study PM060184 Combination With Gemcitabine Selected Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Voluntarily sign date write informed consent prior specific study procedure . 2 . Age ≥ 18 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 ( see APPENDIX 1 ) . 4 . Life expectancy ≥ 3 month . 5 . Patients histologically/cytologically confirm diagnosis advance disease follow tumor progress standard therapy standard therapy exist : Breast cancer noncandidate hormone therapy alone . Epithelial ovarian cancer ( include primary peritoneal disease and/or fallopian tube carcinoma and/or endometrial adenocarcinoma ) . Locally advanced metastatic head neck cancer . Nonsmall cell lung cancer ( NSCLC ) . Germ cell tumor ( GCTs ) . Biliary tract adenocarcinoma . Adenocarcinoma carcinoma unknown primary site ( UKPS ) . Cervix carcinoma . Gastrointestinal stromal tumor ( GIST ) . Urothelial cancer . 6 . Expansion cohort RD : All patient must : Measurable disease accord RECIST v.1.1 ( Choi criterion and/or EORTC metabolic response criterion solid tumor , case GIST ) ; Evaluable disease serum marker case ovarian cancer [ Gynecologic Cancer Intergroup ( GCIG ) specific criterion ] ; Documented disease progression immediately last therapy accord aforementioned criterion . 7 . Washout period : least three week since last anticancer therapy , include radiation therapy ( RT ) 35 % bone marrow ; least three week since last biological/investigational therapy [ exclude monoclonal antibody ( MAbs ) ] ; least four week since last MAbcontaining therapy ; least six week since nitrosoureas mitomycin C ( systemic ) . In case hormonesensitive breast cancer progress hormone therapy , latter must either stop one week continue without change trial . 8 . Adequate bone marrow , renal , hepatic , metabolic function ( assessed ≤ 7 day inclusion study ) : Platelet count ≥ 100 x 109/l , hemoglobin ≥ 9.0 g/dl ANC ≥ 1.0 x 109/l . AST ALT ≤ 3.0 x ULN , independently presence liver metastasis . AP ≤ 2.5 x ULN ( ≤ 5 x ULN diseaserelated ) . Total bilirubin ≤ 1.5 x ULN . International Normalized Ratio ( INR ) &lt; 1.5 ( except patient oral anticoagulation therapy ) . Calculated creatinine clearance ( CrCl ) ≥ 50 ml/minute ( use Cockcroft Gault 's formula ; see APPENDIX 2 ) . Albumin ≥ 2.5 g/dl . 9 . Recovery grade ≤ 1 AE derive previous treatment ( exclude alopecia and/or cutaneous toxicity and/or asthenia ) . 10 . Left ventricular ejection fraction ( LVEF ) echocardiography ( ECHO ) multiplegated acquisition ( MUGA ) within normal range ( accord institutional standard ) . 11 . Women childbearing potential must negative serum urine pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period six week discontinuation treatment . Acceptable method contraception include intrauterine device ( IUD ) , oral contraceptive , subdermal implant and/or double barrier . 1 . Concomitant diseases/conditions : History presence unstable angina , myocardial infarction , congestive heart failure , clinically significant valvular heart disease within last year . Symptomatic arrhythmia uncontrolled arrhythmia require ongoing treatment . Known chronic active hepatitis cirrhosis Active uncontrolled infection [ i.e. , antibiotic , antifungal antiviral intervention indicate surgical procedure ( i.e. , pleural deep abscess drainage ) conduct within 15 day prior inclusion ] . Known human immunodeficiency virus ( HIV ) infection . Current prior history grade ≥ 2 peripheral sensory and/or motor neuropathy . Prior treatment oxaliplatin . Limitation patient 's ability comply treatment followup protocol . Any major illness , Investigator 's judgment , substantially increase risk associate patient 's participation study . 2 . Symptomatic , progressive corticosteroidsrequiring document brain metastasis leptomeningeal disease involvement . 3 . Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feeding . 4 . Patients RT 35 % bone marrow . 5 . Treatment investigational product within 30 day first infusion . 6 . Prior treatment PM060184 . 7 . Prior treatment gemcitabinecontaining therapy advance disease ( adjuvant therapy allow , provide six cycle administer relapse occur six month last drug administration ) , and/or : Patients previously discontinue gemcitabinecontaining regimen due gemcitabinerelated toxicity . 8 . Known hypersensitivity gemcitabine component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>